The 10-day moving average for INBX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
INBX moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INBX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for INBX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where INBX's RSI Oscillator exited the oversold zone, 29 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on INBX as a result. In 68 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for INBX just turned positive on October 20, 2026. Looking at past instances where INBX's MACD turned positive, the stock continued to rise in 32 of 37 cases over the following month. The odds of a continued upward trend are 86%.
Following a +9.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where INBX advanced for three days, in 226 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-27.278) is normal, around the industry mean (2.988). P/E Ratio (-11.057) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. INBX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 47 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
NEUP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 36 cases where NEUP's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NEUP's RSI Oscillator exited the oversold zone, 35 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 63 cases where NEUP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on NEUP as a result. In 73 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for NEUP just turned positive on October 20, 2026. Looking at past instances where NEUP's MACD turned positive, the stock continued to rise in 40 of 49 cases over the following month. The odds of a continued upward trend are 82%.
Following a +5.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where NEUP advanced for three days, in 170 of 192 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
NEUP moved below its 50-day moving average on September 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NEUP crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NEUP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NEUP entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.766) is normal, around the industry mean (2.988). P/E Ratio (-1.137) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.820) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. NEUP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NEUP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
INBX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 47 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 41 | |
P/E GROWTH RATING 1..100 | 61 | |
SEASONALITY SCORE 1..100 | 30 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| INBX | NEUP | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 83% | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 77% | 2 days ago 87% |
| Momentum ODDS (%) | 2 days ago 79% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 86% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 87% |
| Advances ODDS (%) | 2 days ago 78% | 2 days ago 89% |
| Declines ODDS (%) | 4 days ago 82% | 15 days ago 89% |
| BollingerBands ODDS (%) | N/A | 2 days ago 89% |
| Aroon ODDS (%) | 2 days ago 78% | 2 days ago 84% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INBX’s FA Score shows that 1 FA rating(s) are green while NEUP’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INBX’s TA Score shows that 4 TA indicator(s) are bullish while NEUP’s TA Score has 6 bullish TA indicator(s).
INBX (@Biotechnology) experienced а +15.17% price change this week, while NEUP (@Biotechnology) price change was +7.41% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
INBX is expected to report earnings on Nov 13, 2026.
NEUP is expected to report earnings on Nov 13, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, INBX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if INBX jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To INBX | 1D Price Change % | ||
|---|---|---|---|---|
| INBX | 100% | +3.03% | ||
| AXON - INBX | 48% Loosely correlated | +2.54% | ||
| SNTI - INBX | 39% Loosely correlated | -4.48% | ||
| VCYT - INBX | 37% Loosely correlated | +3.19% | ||
| ARRY - INBX | 37% Loosely correlated | +2.40% | ||
| SGMT - INBX | 36% Loosely correlated | +2.57% | ||
More | ||||
A.I.dvisor indicates that over the last year, NEUP has been loosely correlated with BRNS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if NEUP jumps, then BRNS could also see price increases.
| Ticker / NAME | Correlation To NEUP | 1D Price Change % | ||
|---|---|---|---|---|
| NEUP | 100% | +2.65% | ||
| BRNS - NEUP | 50% Loosely correlated | N/A | ||
| SLGL - NEUP | 36% Loosely correlated | -0.14% | ||
| ENSC - NEUP | 31% Poorly correlated | +4.29% | ||
| LKFT - NEUP | 30% Poorly correlated | -0.55% | ||
| INBX - NEUP | 28% Poorly correlated | +3.03% | ||
More | ||||